467 related articles for article (PubMed ID: 15819379)
1. Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium.
Annemans L; Minjoulat-Rey MC; De Knock M; Vranckx K; Czarka M; Gabriel S; Haentjens P
Acta Clin Belg; 2004; 59(6):346-57. PubMed ID: 15819379
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery.
Sullivan SD; Kwong L; Nutescu E
Value Health; 2006; 9(2):68-76. PubMed ID: 16626410
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery.
Gordois A; Posnett J; Borris L; Bossuyt P; Jönsson B; Levy E; de Pouvourville G
J Thromb Haemost; 2003 Oct; 1(10):2167-74. PubMed ID: 14521600
[TBL] [Abstract][Full Text] [Related]
4. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
5. Fondaparinux sodium compared with enoxaparin sodium: a cost-effectiveness analysis.
Bjorvatn A; Kristiansen F
Am J Cardiovasc Drugs; 2005; 5(2):121-30. PubMed ID: 15725043
[TBL] [Abstract][Full Text] [Related]
6. A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery.
Sullivan SD; Davidson BL; Kahn SR; Muntz JE; Oster G; Raskob G
Pharmacoeconomics; 2004; 22(9):605-20. PubMed ID: 15209529
[TBL] [Abstract][Full Text] [Related]
7. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.
Holmes M; Carroll C; Papaioannou D
Health Technol Assess; 2009 Sep; 13 Suppl 2():55-62. PubMed ID: 19804690
[TBL] [Abstract][Full Text] [Related]
8. Cost analysis of fondaparinux versus enoxaparin as venous thromboembolism prophylaxis in hip fracture surgery.
Wade WE; Spruill WJ; Leslie RB
Am J Ther; 2004; 11(3):194-8. PubMed ID: 15133534
[TBL] [Abstract][Full Text] [Related]
9. Cost analysis of fondaparinux versus enoxaparin as venous thromboembolism prophylaxis in elective hip replacement surgery.
Spruill WJ; Wade WE; Leslie RB
Blood Coagul Fibrinolysis; 2004 Oct; 15(7):539-43. PubMed ID: 15389119
[TBL] [Abstract][Full Text] [Related]
10. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W
Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902
[TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients.
Dranitsaris G; Kahn SR; Stumpo C; Paton TW; Martineau J; Smith R; Ginsberg JS;
Am J Cardiovasc Drugs; 2004; 4(5):325-33. PubMed ID: 15449974
[TBL] [Abstract][Full Text] [Related]
12. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.
Tran AH; Lee G
Ann Pharmacother; 2003 Nov; 37(11):1632-43. PubMed ID: 14565815
[TBL] [Abstract][Full Text] [Related]
13. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
Turpie AG; Bauer KA; Eriksson BI; Lassen MR
Arch Intern Med; 2002 Sep; 162(16):1833-40. PubMed ID: 12196081
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery.
Honorato J; Gómez-Outes A; Navarro-Quilis A; Martínez-González J; Rocha E; Planès A
Pharmacoeconomics; 2004; 22(13):885-94. PubMed ID: 15329033
[TBL] [Abstract][Full Text] [Related]
15. [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
Gómez Arrayas I; Suárez Fernández C; Gómez Cerezo JF; Betegón Nicolás L; de Salas-Cansado M; Rubio-Terrés C
Rev Esp Salud Publica; 2012 Dec; 86(6):601-12. PubMed ID: 23325135
[TBL] [Abstract][Full Text] [Related]
16. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States.
Botteman MF; Caprini J; Stephens JM; Nadipelli V; Bell CF; Pashos CL; Cohen AT
Clin Ther; 2002 Nov; 24(11):1960-86; discussion 1938. PubMed ID: 12501885
[TBL] [Abstract][Full Text] [Related]
17. [The cost-effectiveness of fondaparinux compared to enoxaparin as prophylaxis for deep-vein thrombosis in Denmark].
Olsen J; Gundgaard J; Borris LC
Ugeskr Laeger; 2005 May; 167(21):2273-9. PubMed ID: 15962854
[No Abstract] [Full Text] [Related]
18. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
19. Cost analysis: fondaparinux versus preoperative and postoperative enoxaparin as venous thromboembolic event prophylaxis in elective hip arthroplasty.
Wade WE; Spruill WJ; Leslie RB
Am J Orthop (Belle Mead NJ); 2003 Apr; 32(4):201-5. PubMed ID: 12723772
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery.
Turpie AG; Eriksson BI; Lassen MR; Bauer KA
J South Orthop Assoc; 2002; 11(4):182-8. PubMed ID: 12597061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]